Decreased nutrient absorption via intestinal rerouting

Decreased nutrient absorption via intestinal rerouting is not a molecular target, receptor, enzyme, transporter, or other canonical drug target. Instead, it describes a **physiological process** or outcome that results from surgical alteration of the gastrointestinal tract—commonly seen in bariatric procedures such as gastric bypass. These surgeries physically change the route food takes through the intestines to intentionally reduce contact with absorptive surfaces (such as villi and microvilli in the small intestine), thereby decreasing overall nutrient uptake[2]. This approach is used therapeutically for weight loss but can lead to complications like malnutrition and micronutrient deficiencies if not carefully managed. The process involves anatomical changes rather than modulation of a specific molecular entity or pathway[2]. There are no standard abbreviations, aliases, interacting drugs, or direct biomarkers associated with this "target," nor does it fit into established molecular classification systems for therapeutic targets. It should be considered an **incorrect entry** if listed among canonical drug targets because it refers to an effect achieved by surgery rather than a discrete biological molecule or structure amenable to pharmacologic targeting.